Oncology translation, from research priorities to clinical trials

Apex Science supports organisations working to bring cancer discoveries from bench to bedside.

This includes helping medical research charities define research priorities with clinicians, researchers, and patient communities.

It also includes supporting early-stage biotech and diagnostics companies to prepare programs for funding, partnership, and clinical trials.

Across this pathway, Apex Science provides scientific judgement, translational strategy, and senior advisory support to strengthen decision-making and accelerate progress toward patient impact.

Support is typically provided at key points along the oncology translation pathway, when organisations are setting research priorities, preparing programs for funding, or planning clinical development.

Examples include: 

• Clarifying research priorities with medical research charities and philanthropic organisations

• Providing scientific input to funding and portfolio decisions

• Assessing translational readiness of oncology programs

• Developing translational roadmaps from discovery to clinical testing

• Preparing early-stage biotech and diagnostics companies for funding and partnerships

• Fractional Chief Scientific Advisor support for boards and leadership teams

Apex Science is a specialist oncology advisory practice based in Melbourne.

The practice is led by Dr Jasper de Boer (PhD), a translational oncology scientist with more than two decades of experience across cancer research, clinical trials, and funding strategy in Australia and internationally.

He has authored more than 60 peer-reviewed publications in oncology and immunology and is among the top 5% of most-cited researchers in his field.

His work includes leading national multi-institutional research initiatives, shaping competitive funding programs, and supporting charities and early-stage life sciences companies across the oncology translation pathway.

Programs and partnerships developed through this work have secured more than $120 million in research and translational funding and contributed to the development of clinical trials and collaborative research networks.